Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 10/20 | 0.48 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19725826 | 0.91 | BACE1 (0.56) | BACE1BACE2LMNACYP2C9CYP2C19 | |
| SCHEMBL19725813 | 0.86 | BACE1 (0.63) | BACE1BACE2LMNACYP2C9CYP2C19 | |
| SCHEMBL1934384 | 0.85 | BACE1 (0.47) | BACE1BACE2LMNA | |
| SCHEMBL1935428 | 0.85 | BACE1 (0.47) | BACE1BACE2LMNA | |
| SCHEMBL17794147 | 0.84 | BACE1 (0.38) | BACE1BACE2 | |
| SCHEMBL17794133 | 0.82 | BACE1 (0.36) | BACE1BACE2 | |
| SCHEMBL15769264 | 0.78 | BACE1 (0.41) | BACE1BACE2LMNA | |
| SCHEMBL15799730 | 0.78 | BACE1 (0.41) | BACE1BACE2LMNA | |
| SCHEMBL17794122 | 0.78 | BACE1 (0.35) | BACE1BACE2 | |
| SCHEMBL17794149 | 0.78 | BACE1 (0.34) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362248-A1 | C5-C6-OXACYCLIC FUSED IMINOPYRIMIDINONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362248-A1 | C5-C6-OXACYCLIC FUSED IMINOPYRIMIDINONE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, APP, PSEN1 | BACE1 1/4885BACE2 4/4885LMNA 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.